Category: Congress Info

Available Now: Abstract Book of the 8th World Conference on Phage Therapy 2025

Posted on by Targeting Phage Therapy

The Targeting Phage Therapy 2025 Abstract Book is the official scientific publication of the 8th World Conference on Targeting Phage Therapy, held June 10–11, 2025, in Berlin. This comprehensive volume includes over 75 contributions from global experts, including keynote lectures, clinical trial updates, and poster presentations from 27 countries. It explores cutting-edge advances in phage therapy, covering:

• Human and veterinary clinical applications

• Personalized and engineered phage cocktails

• Regulatory pathways and GMP production

• Oncology, microbiome modulation, and antibiotic resistance strategies

With content from world leaders in phage research and medicine, this book offers a rich resource for clinicians, researchers, and biotech innovators. It is a must-have for those seeking to stay at the forefront of next-generation antibacterial therapies.

The book is available now for purchase: https://buy.stripe.com/eVa8Aoeez5aKdDG5kP

Concluding Remarks by Prof. Dr. Christian Willy

Concluding Remarks by Prof. Dr. Christian Willy

Posted on by Targeting Phage Therapy

Prof. Dr. Christian Willy from Military Academic Hospital Berlin, Germany will give concluding remarks and deliver his vision on How phage therapy may evolve in the coming years.


About Prof. Dr. Christian Willy :

Prof. Willy has been actively involved in the field of phage therapy since 2016. He led the first phage treatment in Germany using Good Manufacturing Practice (GMP)-grade phages and has served as the consortial lead of the PhagoFlow project since 2018. His commitment extends to his role as Co-Chairman of the NATO Research Task Group “Reintroduction of phage therapy in military medical space.” Additionally, he has contributed to publications addressing the current state and future prospects of phage therapy in Germany.

Bacteriophage Therapy: From Battlefield Innovation to Civilian Healthcare Renaissance

Bacteriophage Therapy: From Battlefield Innovation to Civilian Healthcare Renaissance

Posted on by Targeting Phage Therapy

Christian Willy

Bacteriophage therapy, once a cornerstone of military medicine, is experiencing a resurgence as a promising solution to antibiotic-resistant infections. Prof. Dr. Christian Willy, a leading figure in this revival, will present his insights at the upcoming 8th World Conference on Targeting Phage Therapy, scheduled for June 10-11, 2025, in Berlin.

Dr. Willy’s presentation, titled “Bacteriophage Therapy: A Renaissance – From Military Medicine to Civilian Healthcare,” will explore the historical use of phages, their decline with the advent of antibiotics, and their modern resurgence. He will highlight NATO and Bundeswehr-led initiatives, including the PhagoFlow project, which have demonstrated phage therapy’s efficacy in treating infected combat wounds. These military applications have paved the way for civilian use, particularly in addressing chronic, multidrug-resistant infections in septic and reconstructive surgeries.

Since 2016, Dr. Willy has been at the forefront of phage therapy in Germany, leading the first treatment using Good Manufacturing Practice (GMP)-grade phages and serving as the consortium lead of the PhagoFlow project since 2018. His role as Co-Chairman of the NATO Research Task Group on reintroducing phage therapy in military medical settings underscores his commitment to this field.

Breathing New Life into Cystic Fibrosis Care: Personalized Phage Therapy Takes Aim at Superbugs

Breathing New Life into Cystic Fibrosis Care: Personalized Phage Therapy Takes Aim at Superbugs

Posted on by Targeting Phage Therapy

In a promising breakthrough against antibiotic-resistant infections, researchers have harnessed personalized bacteriophage therapy to combat Pseudomonas aeruginosa in adults with cystic fibrosis (CF). The innovative approach—designed to exploit bacterial “trade-offs” that weaken resistance or virulence—was used to treat nine CF patients with compassionate-use nebulized phage therapy.

The results were encouraging: bacterial load in patients’ lungs dropped significantly without disturbing the broader microbiome, and no adverse effects were reported. More intriguingly, the therapy induced evolutionary changes in the bacteria that appeared to reduce both drug resistance and harmfulness. Patients also showed improved lung function, suggesting a dual benefit from reduced bacterial density and phage-driven bacterial weakening.

As the world faces a mounting antimicrobial resistance (AMR) crisis, this targeted and evolutionary-informed strategy marks a potential paradigm shift—especially for hard-to-treat infections in chronic conditions like CF.

Dr. Gail L. Stanley, MD, MPH, will share insights from this pioneering work at the upcoming Phage Therapy 2025 conference, where global experts will explore the clinical frontier of bacteriophage-based medicine.

Keynote Speech 2025: Prof. Robert T. Schooley

Posted on by Targeting Phage Therapy
It is a great pleasure to welcome Prof. Robert Schooley, from University of California, San Diego (USA) as a key note speaker during Targeting Phage Therapy 2025, this June in Berlin.
 
He will present a talk on: Phage Therapy 2030: Getting from Here to There.
 
The use of phages in clinical medicine has been accelerating for nearly a decade and is poised to further accelerate over the foreseeable future. By 2030 it is likely that phage use will be substantially more widespread than at present. In his keynote speech, Prof. Schooley will speculate about where phage therapy we be in 2030 and what will it take to get there.
 
About Professor Robert T. Schooley
 
Robert T. Schooley, MD, is an infectious disease specialist and an expert in HIV and hepatitis C (HCV) infection and treatment. Infectious disease specialists care for patients with infections or diseases caused by viruses, bacteria, fungi and parasites. 

His research interests include influenza, global health and international medicine, and the diagnosis and management of infections that cause death and morbidity in resource-limited settings. Dr. Schooley is particularly interested in the origin and development (pathogenesis) of HIV and HIV therapy, and was one of the first researchers to describe the humoral and cellular immune responses to HIV infection.

Dr. Schooley is a professor in the Division of Infectious Diseases within the Department of Medicine at UC San Diego School of Medicine, where he has developed a multidisciplinary research program for hepatitis C.

He leads the Universidade Eduardo Mondlane-UC San Diego Medical Education Partnership Initiative and supervises postdoctoral fellows.

Dr. Schooley is extensively published, having edited numerous books and authored hundreds of articles and book chapters. He serves on the editorial board of several medical journals, including Journal of Acquired Immune Deficiency Syndromes and Clinical Infectious Diseases.

In 2013, Dr. Schooley was honored with the Best Doctors in America and America’s Top Doctors award.

 

Berlin will Host Targeting Phage Therapy 2025 on June 10-11

Berlin will Host Targeting Phage Therapy 2025 on June 10-11

Posted on by Targeting Phage Therapy

It is a great pleasure to announce that the 8th World Congress on Targeting Phage Therapy will be held on June 10-11, 2025, at DoubleTree by Hilton Berlin Ku’damm, Berlin, Germany. 

Don’t miss the chance to join international experts to know more about all the new phage and phage therapy research, applications, and innovations.

Registration.

Book your room

Book your hotel Here

Practical Session: How to Produce, Manufacture, and Bring Phage Products to Market

Practical Session: How to Produce, Manufacture, and Bring Phage Products to Market

Posted on by Targeting Phage Therapy
 
 
A Practical Guide Covering Technical, Regulatory, and Business Aspects
 
Targeting Phage Therapy 2025 is dedicating a practical session to “How to Produce, Manufacture, and Bring Phage Products to Market”.  This session provides a comprehensive and hands-on approach to the entire phage product lifecycle, from laboratory preparation to industrial-scale production and market entry. Experts will address both practical challenges and administrative requirements, ensuring that participants leave with actionable insights.
 
Key Topics Covered:
 
Technical & Manufacturing Aspects
 
  • Good Manufacturing Practices (GMP) for Phage Production – Ensuring compliance with pharmaceutical and industrial regulations
  • Scaling Production: Challenges and solutions in large-scale phage manufacturing
  • Quality Control & Standardization: Developing consistent, safe, and effective phage-based products
 
Regulatory & Administrative Aspects
 
  • Regulatory Pathways for Phage Products – Understanding approval processes for therapeutic, veterinary, and industrial applications
  • Documentation & Compliance – Key administrative requirements for licensing and product registration
  • How to Import Phage Products into Europe – Navigating regulations for importing phages that are available as OTC (over-the-counter) treatments in other countries
  • Who Controls Phage Banks in Europe and Internationally? – Overview of institutions, regulatory bodies, and guidelines governing the collection, storage, and distribution of bacteriophage strains
 
Business & Market Strategy
 
  • Market Access & Commercialization Strategies – How to bring phage products to clinical, veterinary, and food industries
  • Investment & Funding Opportunities – Navigating financial aspects for startups and biotech companies
 
Interactive Q&A
 
This session will answer all practical and administrative questions related to phage production, commercialization, regulation, and international importation, ensuring that researchers, startups, and industry leaders have the tools needed to successfully bring phage-based solutions to market.
 

Industry Showcase:

Manufacturers interested in demonstrating their phage production pipelines and sharing insights are invited to contact us for presentation opportunities.

Targeting Phage Therapy 2024 Replay

Targeting Phage Therapy 2024 Replay

Posted on by Targeting Phage Therapy

Phage Therapy 2024 Replay Access 

You can catch up on all the details of the 7th World Conference of Targeting Phage Therapy by requesting access to the conference recordings for the period of 3 weeks. 

The conference replay includes the 40+ major talks and short orals  presented during the 2 days of Targeting Phage Therapy 2024.

It also comprises the different innovations presented by:

 and others..

Order Recordings.

Phage Therapy 2024 Replay Access + Abstracts Book

Benefit from both the Abstract Book and Recorded Sessions of Phage Therapy 2024 to stay tuned about all phage therapy novelties and not to miss out on the latest innovations and discovery in the vast world of phage applications.

Order the abstract book and recordings.

Phage Therapy 2024 Concluding Remarks by Jean-Paul Pirnay: Towards Personalized Phage Therapy

Phage Therapy 2024 Concluding Remarks by Jean-Paul Pirnay: Towards Personalized Phage Therapy

Posted on by Targeting Phage Therapy

The 7th World Congress on Targeting Phage Therapy 2024 took place on June 20-21 in Malta, attracting over 100 participants from more than 30 countries. The event included over 40 presentations, comprising major talks, short orals, and posters.

Dr. Jean Paul Pirnay concluded the conference with remarks emphasizing the critical role of personalized phage therapy in addressing the global antimicrobial crisis. An increasing number of real-world cases show that personalized phage therapy can be an essential and safe additional tool to help manage the worldwide antimicrobial crisis.

He highlighted the urgent need for hundreds of phages targeting over 30 bacterial species responsible for diverse infections. Defined phage products that are currently being developed target only 9 bacterial species (80% of them target 4 species) and only a handful of (commercially viable) infection types.

Dr. Pirnay stated: “Sustainable personalized phage therapy approaches need to be facilitated through the creation of dedicated regulatory frameworks and the development of devices for the instant and on-site synthetic production of AI predicted therapeutic phages.

Phages are best used in synergy with other antimicrobials, or to quote Dr. Sabrina Green: “Phages Can Make Antibiotics Great Again”.”

Looking ahead, the progress in phage therapy will be a central focus at the Targeting Phage Therapy 2025 conference.

Targeting Phage Therapy 2024 conference replay is now available offering valuable perspectives on the latest advancements in phage therapy. Explore the latest breakthroughs in phage therapy and how they’re tackling antibiotic resistance via a 3 weeks access.

Captured Moments.